Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
PEPTAVO
The Stack Source LLC1908 E 11th Street Austin, TX 78702support@peptavo.com(512) 827-8158DBA: Peptavo
Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
A 503A pharmacy compounds peptides for one named patient; a 503B outsourcing facility makes FDA-inspected batches it can sell as office stock. For most peptides only the 503A door is open. Here is how each works, what office stock really requires, and the 40 amino acid line neither can cross.
A 503A compounding pharmacy makes peptides for one named patient at a time, on a prescription, under the oversight of its state board of pharmacy; a 503B outsourcing facility makes batches under FDA's manufacturing standards and may sell them to your clinic as office stock with no patient name attached. For most peptides the choice is made for you, because an outsourcing facility may compound from bulk powder only when the substance is on FDA's short 503B bulks list or the finished drug is in shortage, and few peptides pass either test.
That leaves 503A as the usual route for compounded peptides, and it makes one question decide most orders: does the vial need a patient's name on it? This guide covers how each pathway works, what office stock actually requires, which peptides a 503B facility can and cannot make, and the size limit that rules out both.
Status as of October 21, 2026. FDA proposed on April 30, 2026 to keep semaglutide, tirzepatide, and liraglutide off the 503B bulks list, and it has not published a final determination. The six peptide families the advisory committee recommended in July 2026 were reviewed for the 503A Bulks List only. We update this page when either moves.
Both sections sit in the Food, Drug, and Cosmetic Act, and FDA summarizes them side by side on its compounding provisions page. For a prescriber ordering peptides, these are the differences that change the order.
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| Prescription |
| Required, for an identified patient |
| Optional; may sell without one |
| Office stock | Not permitted under federal law | Permitted, labeled "Office Use Only" |
| Bulk peptides it may use | Monograph, approved-drug component, 503A Bulks List, or 503A Category 1 | 503B bulks list, a drug on FDA's shortage list, or 503B Category 1 |
| Quality standard | USP chapters as the state adopts them | Current good manufacturing practice |
| Who inspects | State board, with FDA surveillance and for-cause visits | FDA, on a risk-based schedule |
| Reports to FDA | No routine product reports | Every product, each June and December, plus adverse events |
| Where to verify | Your patient's state board license lookup | FDA's registered outsourcing facilities list |
Section 503A, at 21 U.S.C. 353a, exempts a compounded drug from FDA approval, from current good manufacturing practice, and from standard drug labeling, provided it is compounded by a licensed pharmacist or physician for an identified individual patient. Most peptide prescriptions run through this section.
The pharmacy may prepare a limited quantity before a prescription arrives, but only based on a history of prescriptions it has already received for that preparation. FDA's final guidance on the 503A prescription requirement treats that anticipatory batch as the pharmacy's inventory, waiting for named prescriptions. It is not a supply it can send to your office.
The peptide itself must qualify as a bulk drug substance under 503A. It needs a USP or NF monograph, or must be a component of an FDA-approved drug, or must appear on the 503A Bulks List, and nominated substances in FDA's interim Category 1 have a workable basis while FDA evaluates them. The powder must come from an FDA-registered manufacturer with a valid certificate of analysis. Our guide to FDA's compounding categories shows which peptides sit where today.
The pharmacy also may not regularly compound what is essentially a copy of a commercially available drug. A compounded version of an approved peptide needs a documented, patient-specific difference that the prescriber determines matters for that patient.
Section 503B, at 21 U.S.C. 353b, was added by the Drug Quality and Security Act in 2013, after contaminated injections from a compounding pharmacy caused a national fungal meningitis outbreak. It created the outsourcing facility: a single site that compounds sterile drugs, registers with FDA every year, pays an annual fee, follows current good manufacturing practice, reports every product it makes, and is inspected by FDA on a risk-based schedule.
People search for a "503B pharmacy," but the statute does not require an outsourcing facility to be a licensed pharmacy at all, though many states license them anyway. What it gets in exchange for the heavier oversight is the right to compound with or without a patient-specific prescription. That is the whole reason clinics seek one out.
The tradeoff sits in the bulk substance rule. A 503B facility may compound from a bulk drug substance only when that substance is on FDA's 503B bulks list, which admits a substance only on a finding of clinical need, or when the drug made from it is on FDA's drug shortage list at the time of compounding, distribution, and dispensing. Outsourcing facilities have their own interim categories, too, and they do not mirror the 503A ones.
If you want vials on the shelf to administer to whichever patient comes in, only a 503B facility can lawfully supply them. A 503A pharmacy that ships unlabeled stock to a clinic falls outside section 503A, and with it the exemptions that make compounding lawful. Some state pharmacy laws still allow limited office-use compounding, but state permission does not restore the federal exemptions.
A 503A prescription can still end up in your clinic. Many states let the pharmacy ship a patient-specific preparation to the practice for administration there. The vial carries that patient's name, and it is used for that patient and no one else.
A 503B office-stock label must read "Office Use Only" and "Not for resale," alongside the statement "This is a compounded drug," the facility's name and contact details, the lot number, and the expiration date. The statute's wholesaling ban still lets you administer the drug in your clinic or dispense it on a prescription. Handing an office-use vial to a patient to inject at home fits neither exception cleanly. If patients self-inject, write patient-specific prescriptions, and ask counsel before building a program around anything else.
The clinical need standard is narrow. In its May 1, 2026 notice, FDA explained that the 503B bulks list admits a substance only if an attribute of the approved drug makes it medically unsuitable for certain patients and the compounded drug addresses that attribute. Supply backorders, convenience, and a lower price do not count. On that reasoning FDA proposed leaving semaglutide, tirzepatide, and liraglutide off the list.
The GLP-1 drugs show how the shortage route works in practice. While they sat on FDA's shortage list, outsourcing facilities could compound them from bulk. When FDA declared the shortages over in late 2024 and early 2025, that basis ended, and FDA's page on compounding as GLP-1 supply stabilized confirms neither drug currently appears on the 503B bulks list or the shortage list.
Most other peptides used in clinics were never in shortage, because no approved product exists to run short, and few have any 503B status. Some are flagged outright: FDA's safety page places GHRP-2, GHRP-6, and ipamorelin acetate in 503B Category 2. A 503A Category 1 listing does nothing for an outsourcing facility, and the July 2026 committee votes concerned only the 503A list. Before you order from a 503B facility, ask which basis it relies on for that specific peptide, then check it against FDA's 503B pages yourself.
Since March 23, 2020, any alpha amino acid polymer with a defined sequence longer than 40 amino acids counts as a protein, and a protein is a biological product. FDA's notice to compounders is plain about the consequence: biological products are not eligible for the 503A or 503B exemptions, so no compounding pathway exists for them.
That rule moved familiar products, among them chorionic gonadotropin and somatropin, out of compounding entirely. It is also why tesamorelin, at 44 amino acids, is available only as the approved brand. Count the chain before you assume either kind of pharmacy can help, because at 41 amino acids the answer is no for both.
The legal difference shows up in the shipping box. A 503A preparation typically arrives as a ready-to-use liquid labeled for one patient, which has to travel overnight on ice. Cold-chain logistics are the coordination burden new peptide practices underestimate most, and some states make direct shipment of compounded liquids difficult. 503A product also costs more per dose, and no single pharmacy ships every peptide to every state, so most practices keep more than one pharmacy relationship.
Where a 503B product exists for your peptide, it usually comes as lyophilized powder made in larger batches. It ships without a cold chain, is reconstituted with bacteriostatic water, and is refrigerated after mixing, and the batch economics usually make it cheaper. Batch production is held to current good manufacturing practice, but the same checks still apply: read FDA's registered outsourcing facilities list for the last inspection date, any Form 483, and any recall, and ask for the certificate of analysis on your lot.
Work through the order in this sequence, and stop at the first answer.
Many companies run both a 503A pharmacy and a 503B facility. The statute requires every drug compounded inside a registered outsourcing facility to meet section 503B, so the two operate as separate sites. Ask which one your order leaves from, since that decides the label, the paperwork, and the legal status of the vial.
Whatever the route, chart the pharmacy, the section it compounded under, and the bulk substance status you relied on, next to the consent discussion. The peptide consent form carries the sourcing disclosure a compounded prescription calls for. Peptavo's course teaches the full sourcing module, including how to build these pharmacy relationships, alongside accredited peptide CME. For the state rules layered on top of FDA's, start with the US legality guide.
Not under federal law. Section 503A requires a prescription for an identified individual patient, so a 503A pharmacy cannot ship unlabeled office stock. It can usually send a patient-specific preparation to your clinic for administration to that patient, where state law allows.
Only when the peptide has a lawful 503B basis: a place on FDA's 503B bulks list, a finished drug on FDA's shortage list, or an interim 503B Category 1 listing. Few peptides qualify. A peptide's 503A status, including 503A Category 1, does not carry over to an outsourcing facility.
A 503B facility is held to a stricter standard, current good manufacturing practice with FDA inspection, while a 503A pharmacy follows the USP chapters its state enforces. The standard is not the same as the result. Check FDA's inspection record for any outsourcing facility, and vet a 503A pharmacy's sterile compounding and testing directly.
A company can run both, but not in the same facility. Every drug compounded in a registered outsourcing facility must meet section 503B, so companies that offer both operate them at separate sites. Ask which site and which section covers your order.
No. Since March 23, 2020, a defined amino acid chain longer than 40 counts as a protein and is regulated as a biological product, and biological products are excluded from both the 503A and 503B exemptions. Those products are available only as FDA-licensed brands.
No. The committee reviewed the six peptide families for the 503A Bulks List, and even there its vote is advisory until FDA finalizes a rule. Outsourcing facilities work from the separate 503B bulks list, which turns on clinical need.